Sign in
CompletedPhase 1/2

NAD Supplementation and Vascular Health in PAD

Key facts

Who runs it
University of Oklahoma
Where
Oklahoma City, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 1/2
People taking part
8 people enrolled
Started
27 Feb 2023
Ended
30 Dec 2024
Type of study
Interventional
Treatments tested
  • Nicotinamide riboside
Record updated
6 April 2026

Who can take part

Age
55 years to 99 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • diagnosis of PAD
  • intermittent claudication
  • limited walking capacity

Who cannot take part

  • current or prior cerebrovascular complications (including large vessel ischemic stroke with chronic functional impairment)
  • macologically uncontrolled type 2 diabetes, hypercholesterolemia, hypertension
  • major depressive disorder
  • neurodegenerative diseases

Where in United States

  • University of Oklahoma Health Sciences CenterOklahoma City, United States

About the trial

What the trial wants to find out

This pilot open-label clinical trial was designed to investigate whether 4-week supplementation with 1g daily NR impacts endothelial function in peripheral circulation, cerebrovascular hemodynamics, cognitive function in older adults with peripheral artery disease.

The group in the trial

  • NR supplementationTreatment being tested

    1g daily NR

    Treatment: Nicotinamide riboside

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Effect of Nicotinamide Adenine Dinucleotide (NAD) Supplementation on Systemic Vascular Health in Peripheral Artery Disease
Record updated
6 April 2026